SCHEMBL4497481

SCHEMBL4497481

O=C(O)c1ccc2[nH]c(NCC3CCN(Cc4cccc5ccccc45)CC3)nc2c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.44
SIGMAR1 Q99720 2/20 0.43
HDAC1 Q13547 1/20 0.43
HDAC8 Q9BY41 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43
ACHE P22303 1/20 0.42
OPRM1 P35372 2/20 0.41
OPRK1 P41145 2/20 0.41
PIK3CB P42338 1/20 0.41
FAAH O00519 1/20 0.41
OPRL1 P41146 1/20 0.41
USP2 O75604 1/20 0.40
TSHR P16473 1/20 0.40
HSD17B10 Q99714 1/20 0.40
LMNA P02545 2/20 0.40
TP53 P04637 2/20 0.40
THRB P10828 1/20 0.40
HTR2A P28223 2/20 0.40
DRD4 P21917 2/20 0.40
KDM1A O60341 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4509574 0.91 HSD17B10 (0.44) SIGMAR1HDAC1HDAC8HDAC6ACHE
SCHEMBL4505044 0.91 ACHE (0.42) SIGMAR1HDAC1HDAC8HDAC6ACHE
SCHEMBL4496674 0.86 ACHE (0.43) SMN1; SMN2SIGMAR1HDAC1HDAC8HDAC6
SCHEMBL4509816 0.85 OPRM1 (0.43) SIGMAR1HDAC1HDAC8HDAC6ACHE
SCHEMBL4494897 0.84 ACHE (0.43) SIGMAR1HDAC1HDAC8HDAC6ACHE
SCHEMBL4507510 0.82 OPRM1 (0.43) SIGMAR1HDAC1HDAC8HDAC6ACHE
SCHEMBL4503583 0.80 KDM1A (0.53) HDAC1HDAC8HDAC6DRD4KDM1A
SCHEMBL4502250 0.80 ACHE (0.48) SIGMAR1HDAC1HDAC8HDAC6ACHE
SCHEMBL4493806 0.75 ACHE (0.43) SIGMAR1HDAC1HDAC8HDAC6ACHE
SCHEMBL4496486 0.72 GRIN2B (0.48) HDAC1HDAC8HDAC6DRD4KDM1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7517875-B2 Piperidine derivatives having CCR3 antagonism TEIJIN LIMITED (JP) 2009-04-14 US disclosed
US-20070032525-A1 Piperidine derivatives having ccr3 antagonism TEIJIN LIMITED, A JAPANESE BODY CORPORATE (JP) 2007-02-08 US disclosed
EP-1502916-A1 PIPERIDINE DERIVATIVES HAVING CCR3 ANTAGONISM TEIJIN LIMITED (JP) 2005-02-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032525-A1 Piperidine derivatives having ccr3 antagonism CCR3, CCR1, CCR4 SMN1; SMN2 3746/4885SIGMAR1 1754/4885HDAC1 396/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.